Immunotherapy has brought promising breakthroughs to several types of cancer. Cervical cancer has a relatively large number of mutations (gene changes), which may make it more sensitive to immunotherapy drugs and may apply immunotherapy to cervical cancer.
A number of clinical trials are in full swing, and the researchers recently summarized a phase II trial of single drug nivolumab (Opdivo) for recurrent cervical cancer. Among the 24 patients: 19 had cervical cancer, 5 had vaginal cancer, and 26% of cervical cancer patients responded to the drug, which is an encouraging result.
Researchers will continue to improve the single-drug program through further trials, but are also pursuing another approach: combination trials. Studies using single-agent immunotherapy with drugs such as pembrolizumab (Keytruda) or nivolumab show that 15% -25% of patients are active, but the remaining patients are inactive, and there is much room for improvement. For this reason, the researchers are more focused on combined trials of cervical cancer.
Une expérience est en cours pour associer le médicament d'immunothérapie atezolizumab (Tecentriq) à l'agent anti-angiogénique bevacizumab, qui empêche les cellules cancéreuses de former de nouveaux vaisseaux sanguins qui doivent se développer. Le bevacizumab est un médicament actif contre le cancer du col de l'utérus, et il existe des données précliniques selon lesquelles le bevacizumab peut améliorer l'efficacité de l'immunothérapie. Il s'agit donc d'une combinaison passionnante de cancer du col de l'utérus et nous attendons avec impatience les résultats de cette étude.
In another clinical trial, researchers are studying how two immunotherapy drugs, durvalumab (IMFINZI) and tremelimumab, can be combined with radiation therapy to see if radiation can enhance the immune response.
De plus en plus de recherches sur l'immunothérapie du cancer du col de l'utérus ont ajouté de grands espoirs aux patients atteints de cancer du col de l'utérus, et nous attendons avec impatience de meilleurs effets de traitement.
